Figure 2 from INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors

Activity of INX-315 in CCNE1-amplified cancers. A, IC₅₀s for palbociclib and INX-315 for cell lines shown using CellTiter Glo viability assay. All cells were treated for 6 days, n = 3 technical replicates per cell line. B, Cell cycle phase profiles of OVCAR-3 and MKN1 cells treated with INX-315. All cells were treated for 24 hours, n = 3 technical replicates per cell line; error bars are SD. C, Western blots for phosphorylated/total Rb and cyclin A2 in OVCAR3 and MKN1 cells treated with INX-315 for 24 hours. D and E, Tumor growth curves for CCNE1-amplified gastric and ovarian carcinoma models treated with INX-315 at doses shown (GA0103 n = 8 per group; GA0114 n = 8 per group; OVCAR3 n = 10 per group; OV5398 n = 10 per group; error bars represent SEM; P values calculated using two-way ANOVA. all experiments performed once). F, Western blots for phosphorylated/total Rb and cyclin A2 in tumor tissue lysates treated with control vehicle or INX-315. Samples were collected at experimental endpoint from experiments in E.